- Home
- SHOT vs CLGN Comparison
SHOT vs CLGN Comparison
Compare SHOT & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- CLGN
- Stock Information
- Founded
- SHOT 2018
- CLGN 2004
- Country
- SHOT United States
- CLGN Israel
- Employees
- SHOT N/A
- CLGN N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- SHOT Health Care
- CLGN Health Care
- Exchange
- SHOT Nasdaq
- CLGN Nasdaq
- Market Cap
- SHOT 33.1M
- CLGN 37.4M
- IPO Year
- SHOT 2020
- CLGN N/A
- Fundamental
- Price
- SHOT $0.41
- CLGN $2.57
- Analyst Decision
- SHOT
- CLGN Strong Buy
- Analyst Count
- SHOT 0
- CLGN 2
- Target Price
- SHOT N/A
- CLGN $12.50
- AVG Volume (30 Days)
- SHOT 678.1K
- CLGN 12.4K
- Earning Date
- SHOT 05-14-2025
- CLGN 03-26-2025
- Dividend Yield
- SHOT N/A
- CLGN N/A
- EPS Growth
- SHOT N/A
- CLGN N/A
- EPS
- SHOT N/A
- CLGN N/A
- Revenue
- SHOT $701,967.00
- CLGN $515,000.00
- Revenue This Year
- SHOT N/A
- CLGN $2,474.76
- Revenue Next Year
- SHOT N/A
- CLGN $52.63
- P/E Ratio
- SHOT N/A
- CLGN N/A
- Revenue Growth
- SHOT 68.01
- CLGN N/A
- 52 Week Low
- SHOT $0.34
- CLGN $2.54
- 52 Week High
- SHOT $2.40
- CLGN $6.75
- Technical
- Relative Strength Index (RSI)
- SHOT 30.52
- CLGN 26.73
- Support Level
- SHOT $0.34
- CLGN $2.54
- Resistance Level
- SHOT $0.50
- CLGN $2.91
- Average True Range (ATR)
- SHOT 0.04
- CLGN 0.26
- MACD
- SHOT -0.01
- CLGN -0.04
- Stochastic Oscillator
- SHOT 14.42
- CLGN 2.59
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.